Skip to main content
. 2016 Nov 29;6:37821. doi: 10.1038/srep37821

Table 2. Expression alteration of 37 lincRNAs in discovery and replication stages.

Ensembl ID Symbol Discovery stagea
Replication Stageb
Replication Stagec
Log2-FCd P Log2-FCd P Log2-FCd P
ENSG00000261039 RP11-417E7 7.04 1.47E-08 3.49 2.42E-03 7.11 6.45E-05
ENSG00000230838 AC093850 5.84 6.87E-08 9.72 1.19E-10 15.03 1.42E-11
ENSG00000224577 AC017048 3.26 4.31E-05 2.17 2.69E-02 1.03 4.56E-01
ENSG00000253364 RP11-731F5 2.52 4.88E-03 9.31 1.78E-09 13.17 1.16E-08
ENSG00000197308 GATA3-AS1 2.49 2.08E-05 8.27 6.36E-07 5.58 1.43E-02
ENSG00000259093 RP11-1112J20 2.20 6.87E-08 2.02 8.65E-07 2.78 4.02E-06
ENSG00000230615 RP5-1198O20 1.72 2.80E-04 6.53 1.75E-13 7.58 3.50E-09
ENSG00000253161 RP11-150O12 1.68 1.00E-03 4.61 4.12E-05 5.54 9.67E-04
ENSG00000245750 RP11-279F6 1.57 1.17E-03 4.96 1.63E-04 6.07 1.47E-03
ENSG00000214548 MEG3 −1.17 2.47E-07 −2.35 1.15E-07 −0.75 2.18E-01
ENSG00000237697 LINC00312 −1.18 9.13E-03 −3.10 1.24E-04 0.41 7.27E-01
ENSG00000267519 CTD-3252C9 −1.48 6.89E-11 −1.01 4.12E-05 1.33 2.00E-05
ENSG00000267272 RP5-1052I5 −1.56 2.64E-05 −3.02 2.65E-04 −2.37 3.67E-02
ENSG00000255455 RP11-890B15 −1.62 1.28E-04 −1.59 3.60E-04 −1.35 3.52E-02
ENSG00000234076 TPRG1-AS1 −1.74 3.52E-03 −1.93 1.12E-03 −3.37 2.06E-05
ENSG00000262728 AC123768 −1.82 4.90E-08 −1.58 1.27E-02 −3.01 2.80E-04
ENSG00000269930 RP11-932O9 −1.85 9.95E-07 −1.82 8.56E-05 −1.74 7.45E-03
ENSG00000260025 RP11-490M8 −2.15 1.10E-06 −1.99 1.18E-02 −2.78 6.05E-03
ENSG00000260807 RP11-161M6 −2.24 1.64E-06 −1.96 4.49E-02 −5.65 1.34E-05
ENSG00000231246 RP5-965F6 −2.32 4.87E-07 −3.42 5.22E-03 −2.94 7.71E-02
ENSG00000266176 RP11-855A2 −2.39 9.44E-04 −4.16 9.90E-05 0.16 9.21E-01
ENSG00000260693 AC026150 −2.44 1.08E-06 −1.81 3.04E-04 −1.19 8.99E-02
ENSG00000223477 LINC00842 −2.46 8.86E-08 −2.93 7.21E-04 −5.50 1.07E-06
ENSG00000182021 RP11-381O7 −2.57 2.33E-05 −3.26 1.17E-06 −3.67 8.14E-05
ENSG00000258498 DIO3OS −2.68 1.01E-04 −3.34 2.49E-05 −3.76 9.62E-05
ENSG00000269936 MIR145 −2.70 9.87E-13 −1.34 5.52E-04 −1.61 1.80E-03
ENSG00000229645 LINC00341 −2.77 6.89E-11 −3.89 7.12E-06 −2.82 1.50E-02
ENSG00000261064 RP11-1000B6 −2.79 9.95E-07 −1.33 7.23E-03 −1.77 6.81E-03
ENSG00000229108 AC005550 −2.81 2.28E-05 −4.31 4.11E-04 −6.34 7.85E-05
ENSG00000267194 RP1-193H18 −2.81 2.97E-06 −2.32 1.43E-03 −3.05 7.26E-04
ENSG00000260124 RP4-791K14 −2.84 8.18E-06 −1.84 8.56E-06 −2.32 4.72E-05
ENSG00000224307 RP11-344B5 −3.10 7.24E-04 −2.07 2.87E-03 −1.88 3.44E-02
ENSG00000178947 LINC00086 −3.23 1.94E-09 −1.59 2.60E-02 −2.66 5.14E-03
ENSG00000259070 LINC00639 −3.45 2.88E-07 −2.30 8.87E-04 −3.48 1.40E-04
ENSG00000271239 RP11-238F2 −3.67 3.37E-06 −3.19 3.08E-02 −3.86 5.24E-02
ENSG00000262179 RP1-302G2 −4.26 6.95E-07 −5.21 3.39E-06 −4.74 1.56E-03
ENSG00000246430 RP11-16M8 −5.25 2.61E-06 −6.36 4.27E-09 −3.19 3.97E-02

aThe discovery stage from TCGA.

b,cThe replication stage from an independent study; bcomparison between paired tumor and adjacent normal breast tissue from cancer patients; ccomparison between tumor and normal breast tissue from healthy controls.

dLog2-FC denotes log2-transformed fold change between breast tumor and non-tumor samples.